Orexigen Therapeutics, Inc. (OREX) Expected to Post Earnings of -$2.06 Per Share
Equities analysts forecast that Orexigen Therapeutics, Inc. (NASDAQ:OREX) will announce ($2.06) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Orexigen Therapeutics’ earnings. Orexigen Therapeutics reported earnings per share of ($2.67) in the same quarter last year, which would indicate a positive year-over-year growth rate of 22.8%. The business is scheduled to announce its next earnings results on Tuesday, March 27th.
According to Zacks, analysts expect that Orexigen Therapeutics will report full-year earnings of ($10.08) per share for the current fiscal year. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that follow Orexigen Therapeutics.
A number of brokerages have commented on OREX. ValuEngine raised Orexigen Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research raised Orexigen Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th.
Shares of Orexigen Therapeutics (NASDAQ:OREX) traded up $0.03 during midday trading on Friday, reaching $1.21. The company’s stock had a trading volume of 374,876 shares, compared to its average volume of 1,031,867. The company has a current ratio of 2.00, a quick ratio of 1.71 and a debt-to-equity ratio of -2.75. Orexigen Therapeutics has a 52-week low of $0.79 and a 52-week high of $4.48. The firm has a market cap of $22.85, a price-to-earnings ratio of -0.12 and a beta of 1.96.
COPYRIGHT VIOLATION WARNING: “Orexigen Therapeutics, Inc. (OREX) Expected to Post Earnings of -$2.06 Per Share” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/orexigen-therapeutics-inc-orex-expected-to-post-earnings-of-2-06-per-share/1907218.html.
Orexigen Therapeutics Company Profile
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.